Business

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy Designation

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy Designation

articleSichuan Biokin Pharmaceutical Co., Ltd. Class ASeptember 10, 20254/news/announcement-on-voluntary-disclosure-of-iza-bren-egfrher3-dual-antibody-adc-for-injection-for-patients-with-platinum-resistant-recurrent-epithelial-ovarian-cancer-fallopian-tube-cancer-or-primary-peritoneal-cancer-being-included-in-the-list-of-drugs-granted-breakthrough-therapy-designation
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy Designation

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy DesignationThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A